MLPA has been compared with FISH/CISH and IHC with a concordance of 97% (Moerland et al., 2006) and 89% (Purnomosari et al., 2006) respectively, thus suggesting MLPA is a reliable technique to measure HER2 amplification in breast cancer. Here, ERBB2 is linked to breast carcinoma.